CLCC1 Antibody

Immunohistochemistry-Paraffin: CLCC1 Antibody [NBP1-82793]

Immunohistochemistry-Paraffin: CLCC1 Antibody [NBP1-82793] - Staining of human cerebellum shows weak positivity in neuronal processes.

Immunohistochemistry-Paraffin: CLCC1 Antibody [NBP1-82793]

Immunohistochemistry-Paraffin: CLCC1 Antibody [NBP1-82793] - Staining of human endometrium shows strong cytoplasmic positivity in glandular cells.

Immunohistochemistry-Paraffin: CLCC1 Antibody [NBP1-82793]

Immunohistochemistry-Paraffin: CLCC1 Antibody [NBP1-82793] - Staining of human kidney shows moderate cytoplasmic positivity in cells in tubules.

Knockdown Validated: CLCC1 Antibody [NBP1-82793]

Knockdown Validated: CLCC1 Antibody [NBP1-82793] - CLCC1 siRNA interference in ARPE19 cells. Western Blot of SiRNA treated ARPE19 cell lysates probed with CLCC1 antibodies. Lane 1, untransfected lysate; lane 2, transfected with RNAi Max transfection reagent only; lanes 3-12, Increasing CLCC1 and control siRNA amounts from 10 pmol (lanes 3,4) to 70 pmol (lanes 11, 12). CLCC1 proteins migrate at the predicted MW of 67 kDa. The blot shows a dose dependent reduction of CLCC1 protein expression in CLCC1 but not control siRNA treated ARPE19 cells to about 20% of normal. Image collected and cropped by CiteAb from the following publication (https://dx.plos.org/10.1371/journal.pgen.1007504), licensed under a CC-BY license.

Western Blot: CLCC1 Antibody [NBP1-82793] -

Western Blot: CLCC1 Antibody [NBP1-82793] - CLCC1 siRNA interference in ARPE19 cells.(a) Western Blot of SiRNA treated ARPE19 cell lysates probed with CLCC1 antibodies. Lane 1, untransfected lysate; lane 2, transfected with RNAi Max transfection reagent only; lanes 3–12, Increasing CLCC1 & control siRNA amounts from 10 pmol (lanes 3,4) to 70 pmol (lanes 11, 12). CLCC1 proteins migrate at the predicted MW of 67 kDa. The blot shows a dose dependent reduction of CLCC1 protein expression in CLCC1 but not control siRNA treated ARPE19 cells to about 20% of normal. (b) TUNEL assay after siRNA transfection. Left: TUNEL-positive apoptotic cells (green), Second: CLCC1 (red), Third: DAPI (blue, nucleus). Although there is some variation in intensity of individual cells, probably based on cell size, shape, & orientation, staining for CLCC1 is lower overall in the CLCC1 siRNA treated cells than the control siRNA, control, or DNase 1 cells, consistent with the Western blot in Fig 5a. About 10% of CLCC1 siRNA transfected cells were apoptotic (arrows) but there is minimal apoptosis in control siRNA or untransfected cells. DNase I treated cells were 100% TUNEL-positive. Overlays of images from the first three columns are shown in the right column labeled Merged. Scale Bar: 20 μm. (c) Down regulation of CLCC1 induced apoptosis in nearly 10% of the cells (*** P<0.0001, t = 14.63) as compared to approximately 1% of cells treated with the control siRNA & less than 1% of untreated cells. Image collected & cropped by CiteAb from the following publication (https://pubmed.ncbi.nlm.nih.gov/30157172), licensed under a CC0-1.0 license. Not internally tested by Novus Biologicals.